Autologous stem cell transplantation in lymphomas: current indications

Hematopoietic stem cell transplantation is an established curative treatment for a number of conditions including malignant hematologic diseases and non-malignant congenital acquired disorders involving the hematopoietic system some types solid tumors, e.g. germ tumors soft tissue sarcomas. Hodgkin’s disease non-Hodgkin lymphomas can be treated and, in large cases cured, by first-line chemotherapy or radiotherapy. Unlike many other malignancies, relapse not uniformly fatal but usually markedly myelotoxic with high doses (HDC) used relapse. reconstitution either autologous marrow peripheral cells post-chemotherapy has made HDC relatively safe, mortality rates as low 2% centers. The choice conditiong regimen traditionally been based on institutional experience, several regimens are considered standard routinely patients all histologies lymphoma. Each associated its own unique toxicities, individual agents modalities used. Novel targeted immunotherapy approaches, chimeric antigen receptor T-cell therapy, currently being studied clinical trials promising early results, so role could changed. current indications followed management bad prognosis (as consolidation therapy) relapsed/refractory reviewed this paper.